Zobrazeno 61 - 70
of 233
pro vyhledávání: '"Richard F. Little"'
Autor:
John G. Gribben, Wyndham H. Wilson, Michael A. Curran, Sattva S. Neelapu, Nathan Fowler, Thorsten Zenz, Loretta J. Nastoupil, Chan Yoon Cheah, Cliona Grant, Paolo Ghia, Richard F. Little, Catherine M. Bollard, Susan O'Brien, Kieron Dunleavy, Randy D. Gascoyne, Stephen M. Ansell
Publikováno v:
Haematologica. 101:531-540
The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tum
Autor:
Jennifer A. Woyach, John C. Byrd, Jeremy S. Abramson, Amy S. Ruppert, Danielle M. Brander, Richard A. Larson, Jennifer R. Brown, Sreenivasa Nattam, S. E. Coutre, Richard F. Little, Scott E. Smith, Richard Stone, Allison M Booth, Nancy L. Bartlett, Mark R. Litzow, Charles S. Kuzma, Harry P. Erba, Sumithra J. Mandrekar, Wei Ding, Carolyn Owen
Publikováno v:
Journal of Clinical Oncology. 38:e20004-e20004
e20004 Background: IB is a Bruton’s tyrosine kinase inhibitor that showed superior progression-free survival compared with BR in CLL patients (pts) 65 years or older in a randomized phase 3 trial (Woyach et al, NEJM 2018). Pts receiving IB had high
Autor:
Lawrence E. Morris, Polina Shindiapina, Jack W. Hsu, Stephen J. Forman, Gerard Lozanski, Justin Lyberger, Joseph C. Alvarnas, Görgün Akpek, Jennifer Le-Rademacher, Xiaoli Zhang, Amrita Krishnan, Uday R. Popat, Robert A. Baiocchi, Rhonda Kitzler, Craig C. Hofmeister, Lawrence D. Kaplan, Steven M. Devine, Michał T. Seweryn, Ariela Noy, Rebecca Pearson, Mat Makowski, Gregory K. Behbehani, Maciej Pietrzak, Hsiaochi Chang, Richard F. Little, Willis H. Navarro, Elshafa H. Ahmed, Richard F. Ambinder, Adam Mendizabal, Ernesto Ayala, Eric McLaughlin
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S304
Introduction We report the results of a phenotypic and functional analysis of immune reconstitution in HIV(+) patients treated with allogeneic hematopoietic stem cell transplant (allo-HSCT), in comparison with HIV(+) autologous transplant (auto-HSCT)
Autor:
Barbara A. Conley, James V. Tricoli, Keith T. Flaherty, Richard F. Little, Lyndsay Harris, Alice P. Chen, Carlos L. Arteaga, Paul Williams, Robert Gray, Shuli Li, Stanley R. Hamilton, Larry Rubinstein, Edith P. Mitchell, Chris Karlovich, Peter J. O'Dwyer, Nci-Match team, David R. Patton, Lisa M. McShane
Publikováno v:
Molecular Cancer Therapeutics. 18:A079-A079
Introduction: NCI-MATCH, developed by ECOG-ACRIN & NCI, is the largest precision medicine study for pts with refractory malignancy. Over 1100 clinical sites in the National Clinical Trials Network enrolled pts. The purpose of the study is to identify
Autor:
Curtis A. Hanson, Amanda F. Cashen, Harry P. Erba, Susan O'Brien, Esteban Braggio, Paul M. Barr, Michael P Mullane, Victoria Wang, Steven Coutre, Tait D. Shanafelt, Avina K. Singh, Martin S. Tallman, Diane F. Jelinek, Mark R. Litzow, Neil E. Kay, Cong Christina Zhang, Anthony R. Mato, Jose F. Leis, Richard Stone, Jacqueline C. Barrientos, Richard F. Little
Publikováno v:
Blood. 134:33-33
BACKGROUND: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) has been the standard therapy for younger patients with CLL. FCR therapy is particularly effective in patients with immunoglobulin heavy chain variable region (IGH
Autor:
Fangxin Hong, Wojciech Jurczak, Steve Wade, Kazuhito Yamamoto, Krista Hudak, David Scott, John P. Leonard, Thomas E. Witzig, Grzegorz S. Nowakowski, Rebecca L. King, William R. Macon, Jacqueline Russo, Brad S. Kahl, Myron S. Czuczman, Richard F. Little, Jingshan Zhang, Randy D. Gascoyne, Lale Kostakoglu, Jennifer E Amengual, Annalisa Chiappella, Jonathan W. Friedberg, Umberto Vitolo
Publikováno v:
Blood. 134:4092-4092
Background: Standard first-line treatment for patients diagnosed with diffuse large B-cell lymphoma (DLBCL) is the R-CHOP regimen. Despite numerous efforts to improve on this regimen, in all comers and specifically in those with activated B-cell (ABC
Autor:
Richard F. Little, Uday R. Popat, Alexander Prouty, Willis H. Navarro, Xiaoli Zhang, Mateusz Makowski, William Wachsman, Gregory K. Behbehani, Gorgun Akpek, Michał T. Seweryn, Lawrence E. Morris, Jack W. Hsu, Eric McLaughlin, Justin Lyberger, Gerard Lozanski, Polina Shindiapina, Hsiaochi Chang, Craig C. Hofmeister, Stephen J. Forman, Joseph C. Alvarnas, Robert A. Baiocchi, Jennifer Le-Rademacher, Rhonda Kitzler, Ariela Noy, Rebecca Pearson, Maciej Pietrzak, Elshafa H. Ahmed, Richard F. Ambinder, Adam Mendizabal, Lawrence D. Kaplan, Steven M. Devine, Ernesto Ayala
Publikováno v:
Blood. 134:4525-4525
Introduction. Our previous flow cytometry-based comparison of HIV(+) and HIV(-) autologous hematopoietic stem cell transplant (auto-HSCT) recipient immunomes at 56, 180 and 365 days post-transplant to each other and to healthy controls (HCs) showed t
Autor:
Wei Ding, Gerard Lozanski, Allison M Booth, Diane Feldman, Brian T. Hill, Aminah Jatoi, Sumithra J. Mandrekar, Richard F. Little, Richard Stone, Jennifer Le-Rademacher, Elie G Dib, Gabriela Perez, John C. Byrd, Jennifer A. Woyach, Nyla A. Heerema, Amy S. Ruppert
Publikováno v:
Blood. 134:1751-1751
Background The phase 3 trial A041202 solidified the Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib as a standard of care for older patients with previously untreated CLL by showing superior progression-free survival (PFS) as compared with bendamu
Autor:
Annette E. Hay, Annie Im, Min Fang, Sarit Assouline, Anna Moseley, Megan Othus, Sperling M Gail, James M. Foran, Richard F. Little, Roland B. Walter, Laura C. Michaelis, Jerald P. Radich, Harry P. Erba
Publikováno v:
Blood. 134:3905-3905
Background: Less-fit patients with acute myeloid leukemia (AML) or high-risk myelodysplasia (MDS) age 60 years and older constitute the majority of patients with AML/MDS but are not well represented in clinical trials. DNA-methyltransferase inhibitor
Autor:
Fangxin Hong, David W. Scott, William R. Macon, Rebecca L. King, Randy D. Gascoyne, Thomas E. Witzig, Richard F. Little, Brad S. Kahl, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 3, Pp 1-8 (2018)
Blood Cancer Journal
Blood Cancer Journal
ECOG/ACRIN 1412 (E1412) is a randomized, phase II open-label study of lenalidomide/RCHOP vs. RCHOP alone in adults with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) and requires NanoString gene expression profiling (GEP) for cell-of-